期刊
ALZHEIMERS & DEMENTIA
卷 5, 期 5, 页码 427-432出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2009.06.003
关键词
Blood-brain barrier; Brain drug targeting; Endogenous transporters; Biopharmaceuticals
资金
- NIA NIH HHS [R01 AG032244, R01 AG032244-01] Funding Source: Medline
Alzheimer's disease (AD) drug development is limited by the presence of the blood-brain barrier (BBB). More than 98% of all small-molecule drugs, and similar to 100% of all large-molecule drugs, do not cross the BBB. Although the vast majority of AD drug candidates do not cross the BBB, the present-day AD drug-development effort is characterized by an imbalance wherein >99% of the drug-development effort is devoted to central nervous system (CNS) drug discovery, and <1% of drug development is devoted to CNS drug delivery. Future AD drug development needs a concerted effort to incorporate BBB sciences early in the CNS drug discovery process. This goal can be achieved by a reallocation of resources, and an expansion of research efforts in the pure science of BBB biology and the applied science of brain drug-targeting technology. (C) 2009 The Alzheimer's Association. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据